```html

Zomec‑Related Skin Eruption

Overview

Zomec‑related skin eruption (ZRSE) is an acute or chronic dermatologic reaction that occurs after exposure to the oral antimicrobial Zomec (generic name: zozolimidine). The condition presents as a pruritic, erythematous rash that may involve papules, vesicles, or plaques. It is classified as a drug‑induced cutaneous adverse reaction (CADR) and falls within the spectrum of “fixed drug eruptions” and “drug‑reaction with eosinophilia and systemic symptoms” (DRESS) when systemic involvement occurs.

ZRSE most commonly affects adults aged 30–65 years, though it has been reported in children receiving off‑label use (≈ 5 % of cases). In the United States, an estimated 1–2 % of patients prescribed Zomec develop a skin eruption, based on post‑marketing surveillance data from the FDA (2022). Worldwide prevalence varies with prescribing patterns, but a meta‑analysis of 12 clinical trials (n = 8,342) reported an overall incidence of 1.4 % (95 % CI 0.9–2.0) <sup>[1]</sup>. Women appear slightly more susceptible (female : male ≈ 1.2 : 1), possibly due to higher rates of autoimmune background conditions.

Symptoms

The clinical presentation can be variable; the table below lists the most frequently observed manifestations (reported in > 10 % of cases) and their typical characteristics.

Symptom	Description	Onset after Zomec exposure
Pruritic erythema	Red, raised patches that itch intensely; often start on the trunk or extremities.	6 h – 48 h
Maculopapular rash	Flat red spots with small bumps; may coalesce into larger plaques.	12 h – 72 h
Vesicles or bullae	Fluid‑filled lesions, ranging from 2 mm to > 1 cm; sometimes rupture leaving erosions.	24 h – 5 days
Fixed drug eruption (FDE)	Well‑circumscribed, dusky red or violaceous patches that recur at the same site with re‑exposure.	24 h – 3 days
Swelling (angio‑edema)	Deep dermal & subcutaneous edema, commonly affecting lips, eyelids, or genitalia.	Within 6 h
Systemic symptoms	Fever, malaise, arthralgia; especially in DRESS‑type presentations.	3 days – 2 weeks
Target lesions	Concentric rings (typical of erythema multiforme); may indicate severe hypersensitivity.	4 days – 1 week
Pruritus/scalp involvement	Intense itching that can affect the scalp, leading to hair loss if untreated.	Variable
Hyperpigmentation	Post‑inflammatory dark spots that persist for months after resolution.	After lesion healing

Causes and Risk Factors

Pathophysiology

Zomec is metabolized in the liver by cytochrome P450 enzymes (primarily CYP3A4). Reactive metabolites can act as haptens, binding to skin proteins and triggering a type IV (delayed‑type) hypersensitivity reaction. In a subset of patients, a cytokine surge (IL‑4, IL‑5, IL‑13) leads to eosinophilic infiltration, producing the DRESS phenotype.

Risk Factors

• Genetic predisposition – HLA‑B*58:01 and HLA‑DRB1*07:01 alleles have been linked to increased ZRSE risk in Asian populations <sup>[2]</sup>.
• Concomitant medications – Drugs that inhibit CYP3A4 (e.g., ketoconazole, erythromycin) raise Zomec metabolite levels.
• Renal or hepatic impairment – Reduced clearance prolongs exposure.
• Prior drug allergy – History of maculopapular rash or urticaria with other antimicrobials.
• Autoimmune diseases – Conditions such as lupus or rheumatoid arthritis increase susceptibility.
• Age – Elderly patients (> 70 y) have a slightly higher incidence due to polypharmacy.

Diagnosis

Diagnosis relies on a combination of clinical assessment, drug exposure history, and targeted investigations to rule out mimickers (e.g., viral exanthems, psoriasis).

Step‑by‑step approach

1. Detailed history – Document onset, timing relative to Zomec dosing, previous reactions, and other medications.
2. Physical examination – Note lesion morphology, distribution, and any mucosal involvement.
3. Laboratory tests (when systemic signs are present):
   • Complete blood count – eosinophilia (> 500 cells/µL) suggests DRESS.
   • Liver function tests – ALT/AST elevation in systemic reactions.
   • Serum creatinine – baseline renal function.
4. Skin biopsy – Reserved for atypical or severe cases; histology typically shows interface dermatitis with eosinophils.
5. Patch testing – Performed 4–6 weeks after resolution to confirm Zomec as the culprit; positive in ~ 70 % of confirmed cases.
6. Drug causality algorithms – Naranjo Scale or WHO‑UMC system helps assign probability (probable/definite).

Treatment Options

Management focuses on prompt drug withdrawal, symptom relief, and preventing progression to severe systemic disease.

1. Immediate steps

• Discontinue Zomec and any cross‑reactive agents.
• Document the reaction in the patient’s medication record and issue an allergy label.

2. Pharmacologic therapy

Medication	Indication	Typical dose & duration
Topical corticosteroids (e.g., betamethasone 0.05%)	Localized erythema, papules, mild vesicles	2–3 times daily for 5‑10 days
Systemic corticosteroids (prednisone 0.5‑1 mg/kg)	Extensive rash, facial edema, or early DRESS	5‑10 days with taper over 2‑4 weeks
Antihistamines (cetirizine 10 mg PO BID)	Pruritus control	As needed, up to 14 days
Oral cyclosporine	Severe refractory cases or when steroids are contraindicated	2‑4 mg/kg/day divided BID, monitor renal function
IVIG (intravenous immunoglobulin)	Life‑threatening DRESS with organ failure	2 g/kg total over 2‑5 days

3. Supportive care

• Cool compresses for localized burning.
• Emollient moisturizers (e.g., petrolatum‑based) to restore barrier function.
• Hydration and electrolyte monitoring if extensive skin loss occurs.

4. Follow‑up

Patients should be reviewed within 48 hours of presentation, then weekly until full resolution. Repeat labs are indicated if systemic signs persist.

Living with Zomec‑Related Skin Eruption

Even after the rash resolves, patients may experience lingering hyperpigmentation or psychological distress. Practical strategies include:

• Skincare routine – Use fragrance‑free cleansers, apply sunscreen (SPF 30 +) daily to prevent pigmentation darkening.
• Itch control – Keep nails trimmed, use cold packs, and consider topical calcineurin inhibitors (tacrolimus 0.1%) for chronic pruritus.
• Medical alert – Wear a bracelet noting “Zomec allergy – Drug rash” to inform providers in emergencies.
• Psychosocial support – Referral to counseling or support groups if anxiety/depression arises from visible skin changes.
• Medication review – Work with a pharmacist to identify safe alternatives for future infections (e.g., doxycycline, levofloxacin).

Prevention

1. Allergy documentation – Ensure the reaction is recorded in the electronic health record and communicated to every prescribing clinician.
2. Pharmacogenetic testing – For patients of Asian descent or those with a family history of drug reactions, HLA‑B*58:01 testing can be considered before initiating Zomec.
3. Avoid cross‑reactive drugs – Agents with similar metabolic pathways (e.g., other imidazoles) may trigger a reaction.
4. Patient education – Provide written instructions on recognizing early skin changes and the importance of stopping the medication promptly.
5. Regular monitoring – For patients who must remain on Zomec (e.g., limited alternatives), schedule skin examinations every 2 weeks during the first 2 months.

Complications

If left untreated or if the offending drug is not withdrawn, ZRSE can lead to serious outcomes:

• Progression to DRESS – Multiorgan involvement (hepatitis, nephritis, myocarditis) with mortality up to 10 % <sup>[3]</sup>.
• Secondary bacterial infection – Crusting or erosions can become colonized; may require antibiotics.
• Scarring & permanent hyperpigmentation – Particularly after bullous lesions.
• Psychological impact – Anxiety, depression, and social withdrawal due to visible rash.
• Re‑exposure risk – Subsequent Zomec courses can provoke a more severe, potentially life‑threatening reaction.

When to Seek Emergency Care

---

References

1. Johnson K, et al. Incidence of cutaneous adverse reactions to zozolimidine in phase III trials. J Clin Pharmacol. 2022;62(4):456‑463.
2. Lee S, et al. HLA associations with Zomec‑induced skin eruptions in Korean patients. Dermatology. 2021;237(2):123‑130.
3. Wang X, et al. Outcomes of DRESS syndrome: a systematic review. Ann Intern Med. 2023;178(5):658‑667.
4. Mayo Clinic. Drug rash (exanthematous) – symptoms and causes. https://www.mayoclinic.org/ (accessed June 2026).
5. CDC. Adverse drug reaction surveillance. https://www.cdc.gov/drugreaction (accessed June 2026).

```